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Conclusion: Within Aurora, metabolic syndrome is rarely and
variably diagnosed in medical practice, despite clear evidence of
satisfied ATP III and WHO criteria.
Improved Service Efficiency Improves Racial Disparity in
Diabetic Care
Abel Irena, Kushal Patel, David Thompson, Gregory Schleis,
Abiy Gesese, Richard Battiola
Department of Internal Medicine, Aurora Sinai Medical Center;
Aurora University of Wisconsin Medical Group
Background: Racial disparities in diabetes care have been
documented. Disparities also have been shown to affect service
quality and outcome of diabetic care. Analysis of our internal
medicine residency clinic diabetic care management performance
across REAL-G (race, ethnicity, age, preferred language and/or
gender) showed race-based disparity on two outcome measures: 1)
measurement of glycohemoglobin (A1C) at least twice a year; and 2)
target blood pressure of < 140/90.
Purpose: Develop interventions to decrease racial disparities in
diabetes care among patients managed by an internal medicine
residency clinic, as part of the Alliance of Independent Academic
Medical Center’s National Initiative V project.
Methods: Interventions were developed following analysis of
clinic performance data by REAL-G categories, workflow analysis
and multidisciplinary clinic team meetings. A point-of-care A1C
machine was procured and workflow developed using the Plan-DoStudy-Act cycle. Staff training was conducted. A rolling 12 months
data set was obtained from electronic health records. Baseline data
range was December 2014 to November 2015, while endline data
were from January 2016 to December 2016. The interventions were
launched in July 2016. Percentage difference between baseline and
endline outcome indicators was calculated and Z-score test assessed.
Statistical significance was set at P<0.05.
Results: At baseline, 62.9% (401 of 638) of patients who selfidentified as African American/black (AA) had A1C measured at least
twice a year compared to 74.3% (107 of 144) of patients who selfidentified as white/Caucasian (WC), a percentage difference of 11.4%
(P=0.01). For goal blood pressure in diabetics, 71.0% (453 of 638)
of AA met the target as compared to 80.6% (116 of 144) of WC, a
percentage difference of 9.6% (P=0.003). Following the intervention,
a higher percentage of AA patients (71.4% [381 of 534]) had at least
two A1C measured during project period. The outcome also showed
improvement for WC (79.8% [95 of 119]). The percentage difference
between races narrowed to 8.5% (P=0.06). For goal blood pressure,
75.1% of AA achieved the target compared to 81.5% of WC, with
percentage difference narrowing to 6.4% (P=0.14).
Conclusion: Racial disparities in diabetes were confirmed, even
for a clinic setting in which black patients are predominant. Racial
disparity can be improved by implementing interventions that
improve service for all patients.
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Background: The incidence of brain metastasis appears to be
increasing, potentially due to advanced technology that aids early
diagnosis. Patient-derived xenografts (PDX) have high translational
value, as these models retain key functional characteristics of the
patient tumor. PDX models are useful to understand the molecular
basis of tumorigenesis and to identify new treatment targets. However,
generating a first-line PDX model is challenging as engraftment
failure is high. Serial transplanting tumor tissue via mouse-tomouse propagation increases engraftment rates and decreases PDX
development time. Herein we report methods to generate a PDX
cell line from patient-derived tumor tissue that includes the cerebral
aqueduct as a novel intracranial orthotopic implantation site.
Purpose: Develop human tumors in mouse models for therapeutic
purpose.
Methods: Patient-derived brain metastasis tumor tissue was
enzymatically dissociated into a single cell suspension and maintained
in neurocult media supplemented with human recombinant bFGF and
EGF (20 ng/ml). The cells were seeded at a density of 1.0 × 104/cm2
on ultra-low attachment plates and maintained at 37°C with 5% CO2.
PDX models were generated via orthotopic stereotactic surgeries.
Athymic nude mice were anesthetized with an intraperitoneal
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). The
cerebral aqueduct was located using these coordinates from bregma:
A: -5; L: +0.2; V: -2.4. Mice were injected with 5.0 × 104 cells in 2
μl of media at a rate of 0.4 ul/min. Mice were monitored daily for
symptoms of tumor formation. Upon becoming symptomatic, mice
were euthanized and tumor tissue was harvested for both culture and
H&E stain for tumor verification.
Results: Mice injected with primary patient cells (first-generation
mice) developed tumors at 7 weeks (average: 6.77 weeks), secondgeneration mice yielded tumors at 2 weeks (average: 13.5 days), and
third-generation mice replicated results from second-generation mice
(average: 13 days). H&E stain revealed invasive tumor masses in the
ventricular system that extended from the cerebral aqueduct to the
lateral ventricles. Immunohistochemistry analysis confirmed the thirdgeneration cell line retained key characteristics of the patient tumor.
Conclusion: These methods successfully generated a PDX cell line
from patient-derived brain metastasis that demonstrates reliable
tumor formation and phenotypic stability. Importantly, our unique
intracranial implantation site revealed several distinct masses, a
hallmark of brain metastasis in patients.
Decreasing Time to Broad Spectrum Antibiotics for
Septic Patients in the Emergency Department
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Background: Timely administration of broad spectrum antibiotics
has been shown to be directly correlated with decreased mortality
for patients with severe sepsis and septic shock. As such, both the
Surviving Sepsis Campaign and the SEP-1 CMS measure recognize
timely antibiotic administration as a cornerstone of therapy for
patients with severe sepsis or septic shock.
Purpose: Decrease time to broad spectrum antibiotic administration
for septic patients in the emergency department (ED) of Aurora St.
Luke’s Medical Center.
Methods: An alert within the electronic medical record was created
to more rapidly identify potentially septic patients in the ED. After
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